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OBJECTIVE: The human genome contains several types of variations, such as copy number variations, that can
generate specific clinical abnormalities. Different techniques are used to detect these changes, and obtaining
an unequivocal diagnosis is important to understand the physiopathology of the diseases. The objective of this
study was to assess the diagnostic capacity of multiplex ligation-dependent probe amplification and array
techniques for etiologic diagnosis of syndromic patients.
METHODS: We analyzed 93 patients with developmental delay and multiple congenital abnormalities using
multiplex ligation-dependent probe amplifications and arrays.
RESULTS: Multiplex ligation-dependent probe amplification using different kits revealed several changes in
approximately 33.3% of patients. The use of arrays with different platforms showed an approximately 53.75%
detection rate for at least one pathogenic change and a 46.25% detection rate for patients with benign
changes. A concomitant assessment of the two techniques showed an approximately 97.8% rate of con-
cordance, although the results were not the same in all cases. In contrast with the array results, the MLPA
technique detected B70.6% of pathogenic changes.
CONCLUSION: The obtained results corroborated data reported in the literature, but the overall detection rate
was higher than the rates previously reported, due in part to the criteria used to select patients. Although arrays
are the most efficient tool for diagnosis, they are not always suitable as a first-line diagnostic approach because
of their high cost for large-scale use in developing countries. Thus, clinical and laboratory interactions with
skilled technicians are required to target patients for the most effective and beneficial molecular diagnosis.
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’ INTRODUCTION
The human genome contains several types of structural
variations that contribute to genetic diversity and disease
susceptibility (1,2). These structural variations include single
nucleotide alterations, such as point mutations or SNPs (single
nucleotide polymorphisms), small InDels, and copy number
variations (CNVs) (1,3).
CNVs are the most prevalent type of structural variation in
the human genome and can affect the transcription rate,
sequence, structure, and function of genes. These genomic
variations include a range of deletions and duplications larger
than 1 kb and up to several Mb (1,2).
Although these variations often represent only small
genomic segments, they can generate several specific clinical
abnormalities, such as developmental delay (DD) and multi-
ple congenital abnormalities (MCAs) (1-4). However, the
etiology of these disorders is not well understood, making
genetic counseling and treatment difficult (1,2,5).
Different cytogenomic techniques have been used
to detect these changes, including the MLPA (multi-
plex ligation-dependent probe amplification) and array
techniques (1,6,7).DOI: 10.6061/clinics/2017(09)02
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MLPA is a technique that is used to detect deletions and
duplications in genetic diseases of interest, such as the most
common microdeletion/microduplication syndromes and
subtelomeric regions (8,9).
This method is considered a faster alternative and is more
economically viable than other molecular techniques (3,10),
and it allows quantitative genomic screening of target-specific
sequences through simultaneous hybridization and amplifica-
tion via polymerase chain reaction (PCR) using more than
50 different probes in a single reaction (3,8,11,12).
The screening of specific submicroscopic changes via MLPA
detects abnormalities in 5 to 10% of patients with a normal
conventional karyotype (13-15). Thus, in a single test, the
MLPA evaluates patients with characteristics of microdele-
tion/microduplication syndromes and/or patients with
suspected subtelomeric abnormalities (9,15-18).
Although MLPA allows the evaluation of multiple dif-
ferent genomic regions, the main limitation of this technique
is the need for a clinical hypothesis to direct the selection of a
specific kit for analysis (3,8). In contrast, the array technique
does not require a specific clinical diagnosis before use.
The array technique permits the assessment of the CNVs
present in the whole genome of a patient in a single reaction
with a high level of resolution (B0.7 kb), depending on the
platform, types of probes and how they are distributed in
the genome, thus increasing the detection rate of complex
imbalances (4,19,20).
This technique involves the hybridization of probes to
complementary DNA (genomic sequence segments) on a
slide or chip array and subsequent analysis of the fluores-
cence annealed to the target DNA sequences using specific
software (7,21).
Currently, there are several companies that offer this
technology on different platforms, offering slides or chips
with a high density or coverage of the genome. However,
these platforms vary in the number of probes used, and
several of them can interrogate millions of regions in a single
sample (4,7,20,22,23).
The main advantage of the array technique is the ability to
investigate the entire genome in a single experiment with
higher resolution and accuracy compared with traditional
and molecular cytogenetics, as this allows the investigation
of small changes that may have an impact on the phenotype
of patients without a definitive clinical diagnosis (19,22,24).
Thus, arrays have been employed to diagnose patients
with DD and MCAs as well as normal karyotypes, increas-
ing the detection rate of small genomic imbalances and the
diagnosis of patients with clinical phenotypes of unknown
etiology (22,25).
The main limitations of the array technique are the high
cost of large-scale application for developing countries, the
experimental time required (3-5 days), and the expertise
required for classification of the results (CNVs), which can
only be interpreted by a highly qualified professional (25-27).
An unequivocal diagnosis is fundamental to provid-
ing suitable answers regarding the prognosis and risk of
recurrence and can contribute to improving public health
policy (2,25,28).
In developed countries, the array technique is already
being used as the first-line molecular diagnostic test in patients
with MCA (28,29). Recently, Brazil has modified its policies
in the field of genetics, including the clinical genetics policy
guidelines of the Sistema Único de Saúde (SUS), and has pro-
vided financial incentives to cover the costs of genetic testing
and counseling in the national health network (http://
bvsms.saude.gov.br/bvs/publicacoes/diretrizes_atencao_
integral_pessoa_doencas_raras_SUS.pdf).
Thus, genetic services must study the best strategies for
molecular assessment to diagnose each patient referred with
DD and MCA, as the introduction of a single molecular
diagnostic method, such as array technology, as a first-line
assessment method for patients with DD and MCA is
impractical in Brazil due to insufficient public investment
in the health care system and because low-income patients
cannot afford such tests.
In this study, we report our experience with the imple-
mentation and assessment of MLPA using different kits,
array platforms (Affymetrix, Agilent and Illumina), and
probe densities for the molecular diagnostic and scientific
analysis of 93 Brazilian patients with DD and MCA.
’ MATERIALS AND METHODS
This study involved 93 patients who were evaluated using
MLPA and array techniques. The patients presented with
DD and MCAs, such as minor facial anomalies, including a
high forehead, frontal bossing, broad nasal bridge, low-set
ears, ocular hypertelorism, and abnormalities of the eyes,
as well as major congenital defects, such as skeletal and
genital malformations, heart defects, and structural brain
abnormalities.
All patients were previously assessed through conven-
tional cytogenetic analysis to identify their numerical and
structural chromosomal abnormalities; metaphase chromo-
somes were obtained from peripheral blood lymphocyte
samples the patients, and G-banding analysis was performed
using standard procedures. In each case, twenty metaphase
chromosomes were analyzed at a 550-chromosome band
resolution (X5 Mb) and then classified according to the
International System for Human Cytogenetic Nomenclature
2013 (ISCN) guidelines.
Genomic DNA was isolated from 3 mL of peripheral
whole blood from patients using a commercially available
DNA isolation kit (QIAamp DNA Blood Mini Kits, Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. The quality and quantity of the DNA samples were
determined using a Qubits 2.0 Fluorometer (Invitrogen,
Carlsbad, California, USA), and the integrity of the DNAwas
ascertained via agarose gel electrophoresis analysis.
All of the genomic DNAs were screened with the
following three MLPA kits: for the most common microdele-
tion/microduplication syndromes, the SALSA MLPA probe-
mix P064-B2 Mental Retardation-1 kit was employed, which
includes probes for the 1p36 deletion, Williams-Beuren,
Smith-Magenis, Miller-Dieker, 22q11.2 deletion, Prader-Willi/
Angelman, Alagille, Saethre-Chotzen, and Sotos syndromes;
for subtelomeric imbalances, the SALSA MLPA probemix
P036-E1 Human Telomere-3 and SALSA MLPA probemix
P070-B2 Human Telomere-5 kits were used, which include
subtelomeric probes for all chromosomes (MRC-Holland,
Amsterdam, Netherlands).
In several cases, the patients’ genomic DNA samples were
also assessed using specific MLPA kits to confirm the
observed changes. The kits used in these cases were the
SALSA MLPA probemix P250-B1 DiGeorge and SALSA
MLPA probemix P356-A1 Chromosome 22q kits, which are
specific for chromosome 22, and the SALSA MLPA probemix
P029-A1 Williams-Beuren Syndrome kit, which is specific for
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changes in chromosome 7q11 (MRC-Holland, Amsterdam,
Netherlands).
DNA denaturation, hybridization of probes, ligation,
and PCR were performed according to the manufacturer’s
instructions, as described by Schouten et al. (11). Separation
of the amplification products via electrophoresis was per-
formed using an ABI 3500 Genetic Analyzer (Thermo Fisher
Scientific, Waltham, Massachusetts, USA), and the data were
analyzed using GeneMarker software, version 1.6 (www.
softgenetics.com-Softgenetics, State College, Pennsylvania,
USA).
The peak area of each fragment was compared with that of
a control sample, and the results were considered abnormal
when the relative peak-height ratio was less than 0.75
(deletion) or greater than 1.25 (duplication). The details of
the regions and probes detected by each kit can be found at
www.mlpa.com.
The arrays were employed on three different platforms,
from Agilent Technologies (Santa Clara, California, USA),
Affymetrix (Santa Clara, California, USA) and Illumina (San
Diego, California, USA), which differ in the technology used.
On the Agilent platform, we used the Human Genome
CGH Microarray 2x105K slide, containing 105,750 probes
with an average spacing of 22 kb, the SurePrint G3 Human
CGH Microarray 4x180K slide, containing 180,880 probes
distributed throughout the genome with an average spacing
of 13 kb, and the SurePrint G3 Human CGH Microarray
8x60K slide, containing 62,976 probes with an average
spacing of 41 kb.
On the Affymetrix platform, we used the Affymetrix
Genome-Wide Human SNP Array 6.0 chip (1.8 million
genetic markers), which contains 906,600 single-nucleotide
polymorphism (SNP) probes and over 946,000 probes for the
detection of CNVs, with a median physical inter-marker
distance of 1-5 kb, as well as the CytoScan HD chip, which
contains 2,696,550 CNV probes and 749,157 SNP probes,
with an average spacing of 1.1 kb.
On the Illumina platform, we employed the HumanCy-
toSNP-12 BeadChip, with 300,000 oligonucleotide probes
and an average spacing of 9.7 kb, and the CytoSNP-850K,
with 843,888 markers and an average probe spacing of 1.8 kb
across the whole array.
In all samples, amplification, hybridization, staining and
washing were performed according to the manufacturers’
protocols, and the data were extracted by a specific scanner.
The CGH arrays are based on the principle of comparison
between the signal intensities of a sample and commercially
acquired human male control DNA (Promega Corporation,
Madison, Wisconsin, USA). For the SNP arrays (Affymetrix)
and bead arrays (Illumina), only a single hybridization is
performed for the patient DNA, and the signal intensities are
then compared with a reference dataset based on pre-run
reference samples.
The raw data were analyzed using Feature Extraction v9.5,
Affymetrix Chromosome Analysis Suite (ChAS) v.1.2,
or KaryoStudio v1.4.3.0 Build 37 software. The data were
normalized, and log2 ratios were calculated by dividing the
normalized intensity of the sample by the mean intensity
across the reference sample.
The criteria used to determine a CNV included the involv-
ement of at least five consecutive probes sets in a region and
log2 ratio cut-offs of -0.41 and +0.32 for loss and gain,
respectively. The software produced graphical representa-
tions of CNV breakpoints for each sample.
The SNP and bead arrays supply the B allele frequency
(BAF), which represents the proportion of B alleles in
the genotype. A region without evidence of CNVs should
show a log2 ratio near zero and three BAF clusters of 0, 0.5,
and 1, corresponding to the AA, AB, and BB genotypes,
respectively.
All samples were evaluated and were found to be in
accordance with the quality standards.
The results were analyzed according to the American
College of Medical Genetics guidelines (30) using indepen-
dent tests and were compared with the following databanks
of CNVs and classified as benign, pathogenic or VOUS
(variants of uncertain clinical significance): the Database of
Genomic Variants (DGV – http://projects.tcag.ca/variation/),
the Database of Chromosomal Imbalance and Phenotype in
Humans Using Ensembl Resources (DECIPHER – http://
decipher.sanger.ac.uk/) and the UCSC Genome Bioinfor-
matics database (http://genome.ucsc.edu). The genomic
positions are reported according to their mapping on the
GRCh37/hg19 genome build.
Ethics
The Research Ethics Committee of the Hospital das
Clínicas da Faculdade de Medicina da Universidade de
São Paulo (HC-FMUSP) approved this study, and written
informed consent for publication was obtained from the
parents of the patients (CAPPesq no 0619/11).
’ RESULTS
In this study, we assessed 93 patients with DD and MCAs
via the MLPA and array techniques. The patients showed
either a normal karyotype or a karyotype with an undeter-
mined abnormality according to G-banding, which made it
impossible to obtain a conclusive diagnosis.
We found thatB97.8% (91/93) of the results from the two
methods were consistent with each other (all results are
described in Table 1). Among the evaluated patients,B13.2%
(12/91) showed no alterations according to either technique;
B54.9% (50/91) only showed changes in the array analysis;
andB39.9% (29/91) of the patients showed CNVs according
to both techniques (Figure 1).
One case with inconclusive results was found in our
cohort, and further evaluation using other molecular
techniques should be performed to definitively diagnose
this patient. Although the changes observed using both
techniques were consistent, the breakpoint determined by
the array did not correspond exactly to the genomic locali-
zation of the MLPA probe, and there were several array
probes between these two probes.
The MLPA results were inconsistent with the array results
in two cases. We found a duplication in the FZD9 gene in one
case (P064 and P029), and in the other, we identified two
alterations (del 16p13.3 with the P036 kit and del 19p13.3
with the P070 kit) using MLPA, which were confirmed via
independent reactions. However, these alterations were not
identified with the array because none of the array probes
are located at exactly the same position as the MLPA probe.
Several of the MLPA results were inconclusive, but this did
not affect the comparison of the techniques because the
regions targeted by MLPA were repeated in several of the
kits used in this study. Thus, the results were concordant,
and although the results were not the same in all cases, the
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MLPA technique detected B70.6% of the pathogenic CNVs
detected using the array.
MLPA Analysis
The MLPA technique was employed to diagnose all
patients using several different kits. No changes were
detected in B66.7% (62/93) of the patients, and in four
cases, one or two kits showed inconclusive results; however,
these cases did not influence the assessment and interpreta-
tion of the results.
CNVs were detected with at least one of the kits in
B33.3% (31/93) of patients (Figure 2). Approximately 22.6%
(7/31) of these changes were detected by the P064 kit, cor-
responding to one deletion typical of the Williams-Beuren
syndrome, one duplication in chromosome 7q11, and five
deletions of 22q11.2, which were atypical in three patients
and typical in the other two patients. All alterations were
confirmed by the specific P029, P250 and/or P356 kits.
We also detected subtelomeric alterations in B45.2% (14/
31) of the patients. One deletion was detected in two patients;
two duplications in different chromosomes were detected in
one patient; two deletions were found in another patient, one
of which was detected with the P036 kit and the other with the
P070 kit; and the remaining 10 patients showed concomitant
deletions and duplications, all of which were present in the
subtelomeric regions of different chromosomes.
The MLPA test also allowed us to simultaneously detect
CNVs with all of the main kits used in this study (P064, P036
and P070); these changes were identified inB25.8% (8/31) of
the patients.
One atypical duplication (in the PRODH gene) was only
detected by the P356 kit, specific for chromosome 22, and one
deletion in chromosome 8p23 (three probes) was detected
with the P250 kit.
ARRAY Analysis
The array technique was applied to all patients using
different platforms (Agilent, Affymetrix or Illumina) and
chip densities. The results showed that B14% (13/93) of the
patients did not exhibit CNVs, while B86% (80/93) exhibi-
ted several different genomic alterations, including deletions,
duplications and loss of heterozygosity (LOH). These chan-
ges were classified as pathogenic, benign or VOUS.
Among the patients showing changes in the genome, we
observed a 46.25% (37/80) detection rate for patients with
benign and/or VOUS CNVs and a 53.75% (43/80) rate for
patients with at least one pathogenic change (Figure 3).
Among the patients with pathogenic CNVs, B51.2% (22/
43) exhibited only one alteration that was considered path-
ogenic, while B44.2% (19/43) showed at least two changes
with important clinical significance, and B4.6% (2/43) of
patients exhibited three or more pathogenic CNVs, possi-
bly due to complex rearrangements. In several cases, these
patients with pathogenic changes also displayed concomi-
tant benign changes or VOUS.
Regarding the size of the changes, the majority of patients
exhibited benign CNVs or VOUS ranging from 100 to 500 kb
and pathogenic CNVs that were larger than 1 Mb.
’ DISCUSSION
Establishing an unequivocal clinical and molecular diag-
nosis for patients with DD and MCA is essential for
correlating genotypes and phenotypes and making genetic
counseling more effective.
Figure 1 - Cytogenomic map of the raw data of all alterations identified via the MLPA and array techniques. The gray circles represent
the locations of the breakpoints of the alterations identified by both techniques, in which the center circle corresponds to the MLPA
results and the middle circle to the array results. Each bar refers to the position of each identified copy number change: the red bar
refers to deletions, the blue to duplications, and the green to loss of heterozygosity. The genomic positions are reported according to
their mapping on the GRCh38/hg38 genome build from the UCSC Genome Browser.
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With advances in cytogenomic techniques, different
syndromes can be better evaluated. Thus, for certain
changes, specific genes are now highlighted as being
responsible for most of the clinical features of a defined
syndrome, whereas for others it is possible to deter-
mine alterations in an increasing number of critical
regions associated with specific clinical characteristics
(1,6).
Figure 3 - The number of CNVs identified on each chromosome via the array technique. The red bar indicates pathogenic CNVs; the blue
bar indicates benign CNVs; the gray bar indicates VOUS; and the green bar indicates LOH.
Figure 2 - The results of MLPA. The blue bar indicates the number of duplications; the red bar indicates deletions; and the green bar
indicates the number of normal results detected via MLPA.
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Currently, the MLPA technique has become very useful
for the detection of the main microdeletion/microduplication
syndromes and subtelomeric imbalances, as it is a rapid
technique that is able to detect typical changes correlated
with specific phenotypes (e.g., Williams-Beuren syndrome
or deletion of 22q11.2), in addition to being detecting small
and/or atypical deletions and duplications in target regions
(9,15,16). MLPA has the ability to assess more than 45 target
regions in a single reaction without cell culture, making it a
cost-effective and widely used technique for the validation of
other methods, such as array-based analysis (12,15).
In this study, MLPA analysis using the P064 and/or P036
and P070 kits detected alterations in approximately 33.3%
of patients. Using the same combination of MLPA kits,
Jehee et al. (31) identified pathogenic changes in 21.8% of
261 patients with DD and MCA.
In a study performed on 258 patients with intellectual dis-
abilities and dysmorphisms in 2007, the rate of the detection
of alterations using several kits was 10.1%, among which
only 5.8% were changes in regions correlated with syndro-
mes, and 5.0% were associated with subtelomeric regions (15).
In the patients included in the present study, the changes
identified with a specific kit for the main microdeletion/
microduplication syndromes (P064) corresponded to B7.5%
of all samples, or B22.6% of all changes, representing
Williams-Beuren syndrome, duplications of chromosome
7q11 and deletions of chromosome 22q11.2. In addition, sub-
telomeric changes were found in B15.1% of the samples
evaluated via MLPA, or B45.2% of the patients with copy
number changes. In a similar study, the detection rate for
alterations in the regions of the main microdeletion/micro-
duplication syndromes was 6.6%, and the detection rate for
subtelomeric alterations was 7.3% (10).
The percentage of copy number changes detected in the
genome via MLPA depends on the criteria used to select
patients, and the data obtained in this study corroborate the
data reported in the literature for the regions correspond-
ing to the main syndromes. However, the obtained values for
subtelomeric regions were higher than those previously
described by several authors.
A subtelomeric analysis conducted by Koolen et al. (14)
detected changes in 6.7% of 210 patients with idiopathic
intellectual disabilities. Two years later, Palomares et al. (32)
detected alterations in 10% of patients with the same pheno-
typic characteristics using subtelomeric kits.
With the exception of two cases, all of the patients who
presented only subtelomeric abnormalities exhibited two
changes: one deletion associated with one duplication on
different chromosomes, or two deletions or duplications.
This set of changes in the same patients may result from
complex rearrangements and translocations between chro-
mosomes or regions of instability that are susceptible to
rearrangements via DNA repair mechanisms.
We also detected changes with the three main kits used in
this study (P064, P036 and P070) accounting for B25.8% of
the CNVs identified among the abnormal results. These alter-
ations may result from a microdeletion syndrome located
near the telomere of a chromosome, such as 1p36 dele-
tion syndrome, or complex rearrangements between different
regions of chromosomes due to instability and microhomology.
In addition to the changes detected by the main kits used
in this study, we were able to identify an atypical change
involving a single gene (2 exons evaluated) using the P356 kit
and a deletion in 8p23 (3 genes evaluated) using the P250 kit.
These alterations are rare and difficult to detect because they
involve specific genes or exons that are associated with
few clinical characteristics, or a phenotype present in most
patients, making it difficult to determine the correct kit to use.
An important limitation of MLPA is that the signal
intensity of the probes varies according to DNA character-
istics, including those associated with the extraction method,
storage time, elution solution, degree of degradation (if present),
and the presence of several types of contaminants, such as
extraction reagents, proteins, RNAs, and salts. These influences
can be minimized if all samples are prepared by the same
technician using the same method. However, it is not always
possible to eliminate this bias because samples may be sent from
other locations, and storage times and DNA extraction methods
may differ from the standard, which can cause artifacts during
analysis that only a specialist can identify (8,18).
In our analyses using the MLPA technique, 4 patients
showed inconclusive results with one or two of the kits, but
none of these findings limited the detection of changes
because the surveyed regions were represented in the other
kits used in this study. These data highlight the importance
of using different combinations of kits because one kit can act
as a control for another, confirming the alterations detected
and excluding false positive and negative results (10,32).
In a study performed by Marenne et al. (2), MLPA was
used to validate data from arrays. DNA from 56 patients
were analyzed via MLPA in two independent reactions,
providing a concordance rate of 97.25%. Therefore, MLPA is
a reproducible technique.
The sizes and breakpoints of chromosomal abnormalities
can currently be determined with greater precision, accuracy
and sensitivity using array techniques (6,19).
All of the patients included in our study were assessed
using the array technique according to the availability of
platforms or slides/chips in the laboratory (Agilent, Affyme-
trix or Illumina). The slides/chips differ in the technologies
involved (CGH, oligonucleotides or beads) and in the
number and spacing of probes distributed throughout the
genome. Technologies with higher genome coverage provide
more accurate breakpoint data and can be used to diagnose
micro changes or several CNVs that were previously con-
sidered a single alteration (e.g., a normal region interposed
by two affected regions). In these cases, the low coverage of
several arrays may determine those changes to be a single
deletion and not a complex rearrangement that may reflect a
change in the patient’s phenotype (4,19,33).
A total of 93 samples were evaluated, and all of the
different technologies employed proved to be satisfactory for
detecting variations in the genome, which in most cases
corroborated the clinical characteristics of each patient.
The data included results that were considered nor-
mal (without changes) for B14% of the patients. This
rate is much lower than that described in the literature.
In 2013, Vallespín et al. (27) evaluated 540 samples (patients
with learning disabilities, autism and/or multiple congenital
malformations) using a customized array with an average
coverage ofB43 kb and showed that no CNVs were detectable
in 31.85% of the patients. In this study, the samples that were
considered normal were assessed using Agilent 180K (2/13
patients), Agilent 60K (1/13 patients) and Illumina (10/13
patients) arrays, all of which exhibit a high rate of genome
coverage. The results (particularly those from the Illumina
platform; 65 samples), were considered normal because the
majority of the evaluated patients had not received a
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suspected clinical diagnosis. These patients should be further
evaluated and subjected to exome sequencing or targeted
tests searching for mutations in specific genes or gene disrup-
tions due to unbalanced translocations (4,20).
Among the patients who presented alterations in the
genome, the array technique showed that 46.25% of the
patients presented benign changes or changes of uncertain
clinical significance, while 53.75% of the patients presented at
least one pathogenic change.
Among the patients exhibiting alterations of clinical
significance, the majority of patients presented only one
or two pathogenic changes in the genome, which were or
were not combined with other alterations, corresponding to
B51.2% and B44.2% of the patients, respectively. Complex
alterations with three or more pathogenic CNVs in different
regions were observed in approximately 4.6% of the patients.
The detection rate of pathogenic alterations visualized
in this study was much higher than the rates previously
reported in several articles. Rosenberg et al. (34) investigated
81 patients with intellectual disabilities and facial dysmorph-
isms via the CGH array technique and concluded that 16% of
the patients exhibited a pathogenic chromosomal imbalance
related to their phenotype, while 4% of the patients exhibited
changes of uncertain clinical significance. Gijsbers et al. (25)
used several SNP array platforms to investigate patients with
intellectual disabilities and multiple congenital abnormalities
and detected alterations in 22.6% of 318 evaluated patients.
Therefore, array analysis was considered the most appro-
priate test for the initial molecular investigation of patients
with these characteristics and normal karyotypes.
Hochstenbach et al. (28) also recommended arrays as the
first diagnostic test in this patient group. Based on analyzing
many studies, they concluded that the rate of detection using
arrays would correspond to at least 19% of pathogenic
changes. Other studies have shown similar rates, regardless
of the platform selected to diagnose patients with intellectual
disabilities, malformations and/or neurological disorders
and normal karyotypes (20,27,28).
Regarding the size of the observed changes, we identified
the greatest number of patients with pathogenic CNVs that
were larger than 1 Mb. These large changes usually involve
more causative genes of a disease. However, the severity
of the clinical manifestations in patients is not necessarily
directly correlated with the size of the change but is cor-
related with location and gene content. Therefore, a small
change can potentially reflect a more severe phenotype due
to the pathogenicity of the altered gene (1,35).
With the implementation of SNP arrays, it has become
possible to identify changes that were previously undiag-
nosed using CGH arrays. In this study, we identified four
patients with LOH or UPD regions that can be correlated
with recessive disorders (20,24,25).
The main challenge in analyzing the results of the arrays is
determining which changes are significant for each patient,
as it is common to identify more than one change per patient,
and all of the changes could potentially influence the
phenotype in many cases. The identification of benign and
VOUS changes is associated with the increased array density
used for diagnosis, as arrays with a greater number of probes
are able to identify a greater number of microalterations and
determine the breakpoints of these changes with higher
accuracy. However, the identification of regions involving
genes without an established function or regions that do not
contain well-described genes will also increase (24,27,29).
All of the changes detected in the present study were
checked against several international databases, including
the DGV, Decipher and UCSC databases. Nevertheless, a
more appropriate assessment of the changes identified in our
patients would result in the creation of a database with
information specifically from Brazilian people.
Most of the obtained results (B97.8%) were concordant
with each other for the regions investigated. However, not all
of the results were in agreement, as the MLPA technique
covers approximately 45 specific regions of the genome in
each available kit, and this technique therefore depends on a
clinical features and direction toward a specific target.
Approximately 54.9% of the CNVs were not detected via
MLPA compared with array analysis, and higher rates for
this comparison (72-81%) are reported in the literature (2).
Despite the presence of the same alteration, one case was
discordant in relation to the breakpoints detected via array
analysis and the position of the MLPA probe. Therefore,
to obtain a conclusive molecular diagnosis, other techniques
should be applied to reevaluate the exact breakpoints
involved.
All of the techniques employed in this study have
advantages and disadvantages depending on the applica-
tion and could potentially be applied together to obtain a
complete molecular diagnosis.
Our findings showed that the interpretation of genotype-
phenotype correlations in patients with complex genomic
rearrangements is very difficult, but these results can directly
contribute to the elucidation of new syndromes.
Arrays are a powerful tool for the identification and
characterization of genomic abnormalities and can provide
accurate diagnoses of previously unidentified or unex-
plained diseases that are suspected to have a genetic cause,
contributing to appropriate clinical management of the
affected patients. When an array is not available, MLPA
with a combination of three kits (P064, P036 and P070) is a
remarkable tool that can detect abnormalities in patients
with DD and MCA (10,15,31).
Clinical and laboratory interactions with skilled techni-
cians are required to target a patient for the most effective
and beneficial molecular diagnosis, in which an appropriate
clinical hypothesis is crucial for the successful detection of
changes.
Patients exhibiting normal results or benign alterations
may present a clinical phenotype due to balanced rearrange-
ments with disruptions in several genes or mutations in
specific genes. In this case, other molecular techniques are
required to achieve a complete diagnosis, such as exome
sequencing, which can detect changes in 80% of patients with
developmental delays of unknown cause, and analysis using
normal arrays (4,20).
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